Research in Severe Asthma (RISA) Trial
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of the Alair System for the treatment of severe refractory asthma.
This will be a multicenter, randomized controlled study comparing the effects of treatment with the Alair System to standard drug therapy in patients with severe asthma refractory to standard medication therapy. A total of 30 subjects will be randomized 1:1 to the Alair Group (Medical management + Alair Treatment) OR the Control Group (Medical management only).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Multicenter, randomized, clinical trial conducted at 8 Investigational Sites in 3 countries.
Subjects in the Alair group to be administered the Alair treatment in 3 separate bronchoscopy sessions, while subjects in the Control group will complete 3 "Control Visits" to the Physicians office, timed to coincide with the 3 treatment bronchoscopy sessions. Following completion of all three procedures or Control Visits subjects will be evaluated at 6 weeks and 12 weeks. All subjects to remain on their maintenance asthma medications until they are evaluated again at 22 weeks after the last procedure or Control Visit. This phase from the last procedure or Control Visit out to 22 Weeks after the last procedure or Control Visit is termed the Steroid Stable Phase.
Subjects will undergo a 14 week period from 22 Weeks to 36 Weeks (termed the Steroid Wean Phase) during which an attempt will be made to wean them off either their maintenance inhaled corticosteroids (ICS) or, if taking maintenance oral corticosteroids (OCS), their oral steroids. If a subject cannot tolerate the steroid reduction at a particular level (as evidenced by loss of asthma control), they will be stabilized on their last tolerable dose of steroid.
All subjects will maintain their reduced steroid dosage from the end of the Steroid Wean Phase at 36 weeks to their final evaluations at the end of the Study at 52 weeks (termed the Reduced Steroid Phase). All subjects will be exited from the study following completion of the 52 week evaluations.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day. |
Procedure: Bronchial Thermoplasty with the Alair System
Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
Other Names:
|
| Active Comparator: Control Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day. |
Drug: Control
Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
|
Outcome Measures
Primary Outcome Measures
- Respiratory Adverse Events Per Subject [Baseline, 12 Months]
Respiratory adverse events (AEs) per subject reported during the Treatment Period, and Post-Treatment Period (Steroid Stable Phase, and Steroid Wean and Reduced Steroid Phase). Results were calculated by dividing the number of respiratory adverse events during each time period by the number of subjects in each group. Statistics were not calculated.
Secondary Outcome Measures
- Use of Maintenance Medications (Change From Baseline) [Baseline, 12 Months]
Percent Change from Baseline at 12 Months (Steroid Wean and Reduced Steroid Phase) Follow-up Visit in dose of inhaled and/or oral corticosteroids.
- Use of Rescue Medications (Change From Baseline) [Baseline, 12 Months]
Change from Baseline at 22-Weeks (Steroid Stable Phase) and 12 Months (Steroid Wean and Reduced Steroid Phase) Follow-up Visits in use of rescue medications. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms.
- Total Symptom Score (Change From Baseline) [Baseline, 12 Months]
Change from Baseline at 22-Weeks (Steroid Stable Phase) and 12 Months (Steroid Wean and Reduced Steroid Phase) Follow-up Visits in Total Symptom Score. The Total Symptom Score comprises the sum of six asthma symptom measurements recorded in a Daily Diary. Each of these symptoms is scored on a scale of 0 to 3 each day by the subject. The sum of the scores for these 6 symptoms comprises the Total Symptom Score, which measures overall asthma symptoms. The maximum score possible is 18. A lower Total Symptom Score represents better asthma control.
- Pre-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline) [Baseline, 12 Months]
Change from Baseline at 22-Weeks (Steroid Stable Phase) and 12 Months (Steroid Wean and Reduced Steroid Phase) Follow-up Visits in forced expiratory volume in one second (FEV1). FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity.
- Post-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline) [Baseline, 12 Months]
Change from Baseline at 22-Weeks (Steroid Stable Phase) and 12 Months(Steroid Wean and Reduced Steroid Phase) Follow-up Visits in forced expiratory volume in one second (FEV1). FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity.
- Asthma Control Questionnaire (ACQ) Score (Change From Baseline) [Baseline, 12 Months]
Change from Baseline at 22-Weeks (Steroid Stable Phase) and 12 Months (Steroid Wean and Reduced Steroid Phase) Follow-up Visits in Asthma Control Questionnaire (ACQ) score. The ACQ is a self-administered patient questionnaire that assesses individual subject asthma control. The ACQ comprises 6 questions that relate to the patient's asthma symptoms, activity limitations, and daily rescue bronchodilator use, and FEV1. Each question is scored from 0 (Better) to 6 (Worse). The ACQ is based on a one-week recall period. A decrease in the ACQ score indicates better asthma control.
- Asthma Quality of Life Questionnaire (AQLQ) Score (Change From Baseline) [Baseline, 12 Months]
Change from Baseline at 22-Weeks (Steroid Stable Phase) and 12 Months(Steroid Wean and Reduced Steroid Phase) Follow-up Visits in Asthma Quality of Life Questionnaire (AQLQ) score. The AQLQ is a self-administered patient questionnaire that assesses four aspects or domains of daily life for patients with asthma: symptoms, emotional function, activity limitations, and environmental stimuli. The AQLQ is based on a 2-week recall period and consists of 32 questions, each scored from 1 (Worse) to 7 (Better). An increase in the AQLQ score indicates a better quality of life.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Ambulatory adult; age 18-65 years
-
Asthma requiring regular maintenance medication that includes high dose inhaled corticosteroid AND long acting β2 agonist (LABA) with or without other asthma maintenance medications. Oral prednisone ≤30 mg/day, leukotriene modifiers, theophylline or other asthma control drugs may be prescribed at the physician's discretion.
-
Pre-bronchodilator forced expiratory volume in one second (FEV1) ≥50% predicted (patients stabilized on inhaled corticosteroids (ICS) and long acting β2 agonists)
-
PC20 < 4 mg/ml per methacholine inhalation test using standardized methods, for patients with pre-bronchodilator FEV1 ≥60% predicted (or FEV1 > lower limit defined by individual hospital protocol). PC20 is the provocative concentration of Provocholine® (a brand of methacholine chloride) resulting in a drop of FEV1 of 20% or more from Baseline
-
Reversible bronchoconstriction during the 12 months prior to enrollment, as demonstrated by an increase in FEV1 of at least 12% 30 minutes after 4 puffs of short-acting β2 agonist, for patients with pre-bronchodilator FEV1 < 60% predicted (or FEV1 < lower limit defined by individual hospital protocol)
-
Patient must be symptomatic, despite medication with high dose inhaled corticosteroids and LABA, by at least one of the following:
-
Use of rescue medication (short-acting β2 agonist) at least 8 of the 14 days prior to enrollment OR
-
Daytime symptoms at least 10 of the 14 days prior to enrollment
-
Non-smoker x 1 year or greater (if former smoker, less than 10 pack years total smoking history)
-
Patient must be suitable for bronchoscopy in the opinion of the investigator or per hospital guidelines
-
Willingness and ability to give written Informed Consent
-
Willingness and ability to comply with the study protocol, including requirements for taking and abstaining from medications
Exclusion Criteria:
-
Participation in another clinical trial involving respiratory intervention that could affect the outcome measures of this study, within 6 weeks prior to randomization. Patients will be disqualified from the study if they enter another study or fail to comply with prescribed asthma medications.
-
Use of immunosuppressant therapy (e.g., methotrexate).
-
Current or recent lower respiratory tract infection (resolved less than 6 weeks from enrollment testing)
-
History of recurrent (no more than three in the last three months) lower respiratory tract infection requiring antibiotics
-
Presence of other respiratory diseases including emphysema, cystic fibrosis, vocal cord dysfunction, mechanical upper airway obstruction, obstructive sleep apnea, Churg-Strauss syndrome, cardiac dysfunction, allergic bronchopulmonary aspergillosis
-
DLCO (diffusion capacity) < 70% predicted
-
Uncontrolled sinus disease
-
Uncontrolled gastro-esophageal reflux disease
-
Use of implanted electronic device such as a pacemaker or internal cardiac defibrillator
-
Use of external pacemaker
-
Significant co-morbid illness such as cancer, renal failure, liver disease or cerebral vascular disease
-
Post-bronchodilator FEV1 of less than 55% predicted
-
Known systemic hypersensitivity or contraindication to methacholine chloride or other parasympathomimetic agents
-
Known sensitivity to medications required to perform bronchoscopy, including lidocaine, atropine, benzodiazepines and opioids
-
Use of a systemic b-adrenergic blocking agent
-
Other medical criteria.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Boston Scientific Corporation
Investigators
- Study Director: Narinder S Shargill, PhD, Asthmatx, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Protocol #0903-27
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Alair | Control |
|---|---|---|
| Arm/Group Description | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day) plus treatment with the Alair System. | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day). |
| Period Title: Randomized | ||
| STARTED | 17 | 17 |
| COMPLETED | 15 | 17 |
| NOT COMPLETED | 2 | 0 |
| Period Title: Randomized | ||
| STARTED | 15 | 17 |
| COMPLETED | 15 | 17 |
| NOT COMPLETED | 0 | 0 |
| Period Title: Randomized | ||
| STARTED | 15 | 17 |
| COMPLETED | 15 | 17 |
| NOT COMPLETED | 0 | 0 |
| Period Title: Randomized | ||
| STARTED | 15 | 17 |
| COMPLETED | 15 | 17 |
| NOT COMPLETED | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | Alair | Control | Total |
|---|---|---|---|
| Arm/Group Description | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day) plus treatment with the Alair System. | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day). | Total of all reporting groups |
| Overall Participants | 15 | 17 | 32 |
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
39.13
(12.97)
|
42.06
(12.57)
|
40.69
(12.64)
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
9
60%
|
7
41.2%
|
16
50%
|
| Male |
6
40%
|
10
58.8%
|
16
50%
|
| Region of Enrollment (participants) [Number] | |||
| Canada |
4
26.7%
|
6
35.3%
|
10
31.3%
|
| United Kingdom |
10
66.7%
|
9
52.9%
|
19
59.4%
|
| Brazil |
1
6.7%
|
2
11.8%
|
3
9.4%
|
Outcome Measures
| Title | Respiratory Adverse Events Per Subject |
|---|---|
| Description | Respiratory adverse events (AEs) per subject reported during the Treatment Period, and Post-Treatment Period (Steroid Stable Phase, and Steroid Wean and Reduced Steroid Phase). Results were calculated by dividing the number of respiratory adverse events during each time period by the number of subjects in each group. Statistics were not calculated. |
| Time Frame | Baseline, 12 Months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Alair | Control |
|---|---|---|
| Arm/Group Description | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day) plus treatment with the Alair System. | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day). |
| Measure Participants | 15 | 17 |
| Treatment Period |
9.1
|
3.4
|
| Steroid Stable Phase |
2.6
|
2.2
|
| Steroid Wean and Reduced Steroid Phase |
5.5
|
5.3
|
| Title | Use of Maintenance Medications (Change From Baseline) |
|---|---|
| Description | Percent Change from Baseline at 12 Months (Steroid Wean and Reduced Steroid Phase) Follow-up Visit in dose of inhaled and/or oral corticosteroids. |
| Time Frame | Baseline, 12 Months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Alair | Control |
|---|---|---|
| Arm/Group Description | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day) plus treatment with the Alair System. | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day). |
| Measure Participants | 15 | 17 |
| Oral Corticosteroids (OCS) |
-63.5
(45.4)
|
-26.2
(40.7)
|
| Inhaled Corticosteroids (ICS) |
-28.6
(30.4)
|
-20.0
(32.9)
|
| Title | Use of Rescue Medications (Change From Baseline) |
|---|---|
| Description | Change from Baseline at 22-Weeks (Steroid Stable Phase) and 12 Months (Steroid Wean and Reduced Steroid Phase) Follow-up Visits in use of rescue medications. Rescue medications for asthma are short-acting beta-agonists that bring quick relief of asthma symptoms. |
| Time Frame | Baseline, 12 Months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Alair | Control |
|---|---|---|
| Arm/Group Description | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day) plus treatment with the Alair System. | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day). |
| Measure Participants | 15 | 17 |
| Steroid Stable Phase |
-26.56
(40.05)
|
-1.47
(11.66)
|
| Steroid Wean and Reduced Steroid Phase |
-25.56
(31.19)
|
-6.07
(12.43)
|
| Title | Total Symptom Score (Change From Baseline) |
|---|---|
| Description | Change from Baseline at 22-Weeks (Steroid Stable Phase) and 12 Months (Steroid Wean and Reduced Steroid Phase) Follow-up Visits in Total Symptom Score. The Total Symptom Score comprises the sum of six asthma symptom measurements recorded in a Daily Diary. Each of these symptoms is scored on a scale of 0 to 3 each day by the subject. The sum of the scores for these 6 symptoms comprises the Total Symptom Score, which measures overall asthma symptoms. The maximum score possible is 18. A lower Total Symptom Score represents better asthma control. |
| Time Frame | Baseline, 12 Months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Alair | Control |
|---|---|---|
| Arm/Group Description | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day) plus treatment with the Alair System. | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day). |
| Measure Participants | 15 | 17 |
| Steroid Stable Phase |
-1.75
(2.58)
|
-0.89
(1.84)
|
| Steroid Wean and Reduced Steroid Phase |
-1.37
(2.61)
|
-1.21
(1.63)
|
| Title | Pre-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline) |
|---|---|
| Description | Change from Baseline at 22-Weeks (Steroid Stable Phase) and 12 Months (Steroid Wean and Reduced Steroid Phase) Follow-up Visits in forced expiratory volume in one second (FEV1). FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity. |
| Time Frame | Baseline, 12 Months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Alair | Control |
|---|---|---|
| Arm/Group Description | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day) plus treatment with the Alair System. | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day). |
| Measure Participants | 15 | 17 |
| Steroid Stable Phase |
14.91
(17.40)
|
-0.94
(22.34)
|
| Steroid Wean and Reduced Steroid Phase |
7.97
(19.13)
|
1.89
(15.00)
|
| Title | Post-Bronchodilator FEV1 (Percent Predicted) (Change From Baseline) |
|---|---|
| Description | Change from Baseline at 22-Weeks (Steroid Stable Phase) and 12 Months(Steroid Wean and Reduced Steroid Phase) Follow-up Visits in forced expiratory volume in one second (FEV1). FEV1 is the volume of air expired during the first second of a maximal effort expiration started at total lung capacity. |
| Time Frame | Baseline, 12 Months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Alair | Control |
|---|---|---|
| Arm/Group Description | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day) plus treatment with the Alair System. | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day). |
| Measure Participants | 15 | 17 |
| Steroid Stable Phase |
5.74
(8.56)
|
-0.82
(16.78)
|
| Steroid Wean and Reduced Steroid Phase |
2.76
(11.57)
|
-1.90
(11.97)
|
| Title | Asthma Control Questionnaire (ACQ) Score (Change From Baseline) |
|---|---|
| Description | Change from Baseline at 22-Weeks (Steroid Stable Phase) and 12 Months (Steroid Wean and Reduced Steroid Phase) Follow-up Visits in Asthma Control Questionnaire (ACQ) score. The ACQ is a self-administered patient questionnaire that assesses individual subject asthma control. The ACQ comprises 6 questions that relate to the patient's asthma symptoms, activity limitations, and daily rescue bronchodilator use, and FEV1. Each question is scored from 0 (Better) to 6 (Worse). The ACQ is based on a one-week recall period. A decrease in the ACQ score indicates better asthma control. |
| Time Frame | Baseline, 12 Months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Alair | Control |
|---|---|---|
| Arm/Group Description | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day) plus treatment with the Alair System. | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day). |
| Measure Participants | 15 | 17 |
| Steroid Stable Phase |
-1.04
(1.03)
|
-0.13
(1.00)
|
| Steroid Wean and Reduced Steroid Phase |
-0.99
(0.83)
|
-0.22
(0.78)
|
| Title | Asthma Quality of Life Questionnaire (AQLQ) Score (Change From Baseline) |
|---|---|
| Description | Change from Baseline at 22-Weeks (Steroid Stable Phase) and 12 Months(Steroid Wean and Reduced Steroid Phase) Follow-up Visits in Asthma Quality of Life Questionnaire (AQLQ) score. The AQLQ is a self-administered patient questionnaire that assesses four aspects or domains of daily life for patients with asthma: symptoms, emotional function, activity limitations, and environmental stimuli. The AQLQ is based on a 2-week recall period and consists of 32 questions, each scored from 1 (Worse) to 7 (Better). An increase in the AQLQ score indicates a better quality of life. |
| Time Frame | Baseline, 12 Months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Alair | Control |
|---|---|---|
| Arm/Group Description | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day) plus treatment with the Alair System. | Standard-of-care therapy of high dose inhaled corticosteroids (ICS) + long acting beta agonists (LABA) ± oral corticosteroids (OCS) (≤ 30 mg/day). |
| Measure Participants | 15 | 17 |
| Steroid Stable Phase |
1.21
(1.05)
|
0.15
(0.75)
|
| Steroid Wean and Reduced Steroid Phase |
1.53
(0.79)
|
0.42
(0.82)
|
Adverse Events
| Time Frame | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | ||||||||||||
| Arm/Group Title | Alair (Treatment Period) | Control (Treatment Period) | Alair (Steroid Stable Phase) | Control (Steroid Stable Phase) | Alair (Steroid Wean and Reduced Steroid Phases) | Control (Steroid Wean and Reduced Steroid Phases) | ||||||
| Arm/Group Description | ||||||||||||
All Cause Mortality |
||||||||||||
| Alair (Treatment Period) | Control (Treatment Period) | Alair (Steroid Stable Phase) | Control (Steroid Stable Phase) | Alair (Steroid Wean and Reduced Steroid Phases) | Control (Steroid Wean and Reduced Steroid Phases) | |||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | / (NaN) | / (NaN) | / (NaN) | / (NaN) | ||||||
Serious Adverse Events |
||||||||||||
| Alair (Treatment Period) | Control (Treatment Period) | Alair (Steroid Stable Phase) | Control (Steroid Stable Phase) | Alair (Steroid Wean and Reduced Steroid Phases) | Control (Steroid Wean and Reduced Steroid Phases) | |||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 5/15 (33.3%) | 1/17 (5.9%) | 4/15 (26.7%) | 1/17 (5.9%) | 2/15 (13.3%) | 1/17 (5.9%) | ||||||
| Hepatobiliary disorders | ||||||||||||
| Gallbladder Pain | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Nervous system disorders | ||||||||||||
| Headache | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Respiratory, thoracic and mediastinal disorders | ||||||||||||
| Atelectasis | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Chest Discomfort | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Cough | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Dyspnoea | 3/15 (20%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Dyspnoea/Wheezing | 1/15 (6.7%) | 0/17 (0%) | 2/15 (13.3%) | 0/17 (0%) | 2/15 (13.3%) | 1/17 (5.9%) | ||||||
| Respiratory Failure | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Surgical and medical procedures | ||||||||||||
| Hernia Repair | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
Other (Not Including Serious) Adverse Events |
||||||||||||
| Alair (Treatment Period) | Control (Treatment Period) | Alair (Steroid Stable Phase) | Control (Steroid Stable Phase) | Alair (Steroid Wean and Reduced Steroid Phases) | Control (Steroid Wean and Reduced Steroid Phases) | |||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 15/15 (100%) | 17/17 (100%) | 15/15 (100%) | 15/17 (88.2%) | 15/15 (100%) | 15/17 (88.2%) | ||||||
| Cardiac disorders | ||||||||||||
| Palpitations | 1/15 (6.7%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 2/15 (13.3%) | 0/17 (0%) | ||||||
| Endocrine disorders | ||||||||||||
| Thyroid Pain | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Eye disorders | ||||||||||||
| Conjunctivitis | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Eye Inflammation | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Eye Pruritis | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Gastrointestinal disorders | ||||||||||||
| Abdominal Discomfort | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Abdominal Pain | 4/15 (26.7%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | 1/15 (6.7%) | 1/17 (5.9%) | ||||||
| Abdominal Pain Lower | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Abdominal Pain Upper | 0/15 (0%) | 2/17 (11.8%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 1/17 (5.9%) | ||||||
| Chapped Lips | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Diarrhoea | 3/15 (20%) | 4/17 (23.5%) | 2/15 (13.3%) | 1/17 (5.9%) | 1/15 (6.7%) | 2/17 (11.8%) | ||||||
| Dyspepsia | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Gastroesophageal Reflux Disease | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Nausea | 4/15 (26.7%) | 1/17 (5.9%) | 1/15 (6.7%) | 1/17 (5.9%) | 0/15 (0%) | 2/17 (11.8%) | ||||||
| Pancreatic Cyst | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Rectal Haemorrhage | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Stomach Discomfort | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Tooth Fracture | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Toothache | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Vomiting | 3/15 (20%) | 3/17 (17.6%) | 1/15 (6.7%) | 0/17 (0%) | 2/15 (13.3%) | 0/17 (0%) | ||||||
| General disorders | ||||||||||||
| Difficulty In Walking | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Fatigue | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 3/17 (17.6%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Influenza Like Illness | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Oedema | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Oedema Peripheral | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Pyrexia | 1/15 (6.7%) | 2/17 (11.8%) | 1/15 (6.7%) | 1/17 (5.9%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Thirst | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Hepatobiliary disorders | ||||||||||||
| Gallbladder Pain | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Immune system disorders | ||||||||||||
| Hypersensitivity | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 1/17 (5.9%) | ||||||
| Infections and infestations | ||||||||||||
| Cystitis | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Ear Infection | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 1/17 (5.9%) | ||||||
| Herpes Simplex | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Infected Insect Bite | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Infection | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Influenza | 2/15 (13.3%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Infusion Site Infection | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Laryngitis | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Localised Infection | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Nasopharyngitis | 3/15 (20%) | 3/17 (17.6%) | 2/15 (13.3%) | 1/17 (5.9%) | 4/15 (26.7%) | 4/17 (23.5%) | ||||||
| Oral Candidiasis | 2/15 (13.3%) | 1/17 (5.9%) | 3/15 (20%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Otitis Media | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Sinusitis | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Subcutaneous Abscess | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Tooth Abscess | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Tooth Infection | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Urinary Tract Infection | 2/15 (13.3%) | 1/17 (5.9%) | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Vaginal Candidiasis | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Vaginal Infection | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Wound Infection | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Injury, poisoning and procedural complications | ||||||||||||
| Anaesthetic Complication | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Arthropod Sting | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Contusion | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 4/15 (26.7%) | 1/17 (5.9%) | ||||||
| Fall | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Joint Injury | 1/15 (6.7%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Ligament Sprain | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Limb Injury | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Meniscus Lesion | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Post Procedural Pain | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Skin Laceration | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Investigations | ||||||||||||
| Weight Increased | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Metabolism and nutrition disorders | ||||||||||||
| Anorexia | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Dehydration | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Musculoskeletal and connective tissue disorders | ||||||||||||
| Arthralgia | 1/15 (6.7%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 1/17 (5.9%) | ||||||
| Arthropathy | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Back Pain | 1/15 (6.7%) | 1/17 (5.9%) | 2/15 (13.3%) | 3/17 (17.6%) | 1/15 (6.7%) | 2/17 (11.8%) | ||||||
| Chest Wall Pain | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Joint Swelling | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Localised Osteoarthritis | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Muscle Cramp | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Musculoskeletal Chest Pain | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Musculoskeletal Stiffness | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Myalgia | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Pain In Extremity | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 1/17 (5.9%) | ||||||
| Nervous system disorders | ||||||||||||
| Dizziness | 4/15 (26.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Dysgeusia | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Headache | 3/15 (20%) | 4/17 (23.5%) | 1/15 (6.7%) | 3/17 (17.6%) | 4/15 (26.7%) | 2/17 (11.8%) | ||||||
| Lethargy | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 2/15 (13.3%) | 0/17 (0%) | ||||||
| Neuropathic Pain | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Paraesthesia | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Sinus Headache | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Syncope | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Tremor | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Psychiatric disorders | ||||||||||||
| Depression | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 2/15 (13.3%) | 0/17 (0%) | ||||||
| Insomnia | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 1/17 (5.9%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Irritability | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Renal and urinary disorders | ||||||||||||
| Pollakiuria | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Reproductive system and breast disorders | ||||||||||||
| Breast Mass | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Ovarian Cyst | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Respiratory, thoracic and mediastinal disorders | ||||||||||||
| Asthma | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Atelectasis | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Breath Sounds Decreased | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Bronchial Irritation | 2/15 (13.3%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Bronchitis | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Chest Discomfort | 4/15 (26.7%) | 1/17 (5.9%) | 1/15 (6.7%) | 2/17 (11.8%) | 2/15 (13.3%) | 6/17 (35.3%) | ||||||
| Chest Pain | 5/15 (33.3%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 1/17 (5.9%) | ||||||
| Cough | 11/15 (73.3%) | 6/17 (35.3%) | 2/15 (13.3%) | 4/17 (23.5%) | 6/15 (40%) | 4/17 (23.5%) | ||||||
| Crackles Lung | 1/15 (6.7%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Dyspnoea | 9/15 (60%) | 5/17 (29.4%) | 5/15 (33.3%) | 7/17 (41.2%) | 8/15 (53.3%) | 10/17 (58.8%) | ||||||
| Dyspnoea Exacerbated | 0/15 (0%) | 2/17 (11.8%) | 2/15 (13.3%) | 0/17 (0%) | 1/15 (6.7%) | 4/17 (23.5%) | ||||||
| Epistaxis | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 2/15 (13.3%) | 0/17 (0%) | ||||||
| Haemoptysis | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Hoarseness | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 1/17 (5.9%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Hypoxia | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Lower Respiratory Tract Infection | 2/15 (13.3%) | 5/17 (29.4%) | 2/15 (13.3%) | 2/17 (11.8%) | 6/15 (40%) | 2/17 (11.8%) | ||||||
| Nasal Congestion | 3/15 (20%) | 3/17 (17.6%) | 2/15 (13.3%) | 1/17 (5.9%) | 3/15 (20%) | 4/17 (23.5%) | ||||||
| Nocturnal Dyspnoea | 1/15 (6.7%) | 1/17 (5.9%) | 3/15 (20%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Pharyngolaryngeal Pain | 3/15 (20%) | 1/17 (5.9%) | 0/15 (0%) | 1/17 (5.9%) | 2/15 (13.3%) | 0/17 (0%) | ||||||
| Postnasal Drip | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Productive Cough | 8/15 (53.3%) | 4/17 (23.5%) | 2/15 (13.3%) | 4/17 (23.5%) | 8/15 (53.3%) | 1/17 (5.9%) | ||||||
| Respiratory Failure | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Respiratory Tract Infection | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Rhinitis | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 2/15 (13.3%) | 1/17 (5.9%) | ||||||
| Sputum Discoloured | 6/15 (40%) | 2/17 (11.8%) | 0/15 (0%) | 2/17 (11.8%) | 3/15 (20%) | 4/17 (23.5%) | ||||||
| Tracheobronchitis | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Upper Respiratory Tract Infection | 1/15 (6.7%) | 3/17 (17.6%) | 3/15 (20%) | 1/17 (5.9%) | 6/15 (40%) | 4/17 (23.5%) | ||||||
| Wheezing | 11/15 (73.3%) | 4/17 (23.5%) | 6/15 (40%) | 2/17 (11.8%) | 5/15 (33.3%) | 10/17 (58.8%) | ||||||
| Skin and subcutaneous tissue disorders | ||||||||||||
| Dandruff | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Dermatitis Allergic | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Dry Skin | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Rash | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Skin Chapped | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | ||||||
| Swelling Face | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Surgical and medical procedures | ||||||||||||
| Arthroscopic Surgery | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 1/17 (5.9%) | ||||||
| Hernia Repair | 0/15 (0%) | 1/17 (5.9%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Nail Operation | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Tooth Extraction | 0/15 (0%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
| Vascular disorders | ||||||||||||
| Hypertension | 1/15 (6.7%) | 0/17 (0%) | 1/15 (6.7%) | 0/17 (0%) | 1/15 (6.7%) | 1/17 (5.9%) | ||||||
| Hypotension | 1/15 (6.7%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | 0/15 (0%) | 0/17 (0%) | ||||||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
| Name/Title | G Mark Grubb, RN, CCRA |
|---|---|
| Organization | Boston Scientific Corporation |
| Phone | 412-716-0717 |
| Mark.Grubb@bsci.com |
- Protocol #0903-27